Post-Market Surveillance for Medical Devices Registered in the UK (UKCA)

After UKCA registration, post-market surveillance (PMS) is a core compliance requirement to maintain certificate validity and market access. Manufacturers must establish a PMS system in accordance with the UK Medical Devices Regulations 2002 (SI 2002 No. 618, as amended), including proactive collection and analysis of post-market data, preparation of Periodic Safety Update Reports (PSURs), implementation of Corrective and Preventive Actions (CAPAs), and reporting of serious adverse events to the competent authority (MHRA).

Core Requirements

Manufacturers must create a PMS system that includes active data collection and analysis, PSUR writing, CAPA implementation, and serious adverse event reporting to MHRA. The system must be based on the product's risk classification and integrated with the ISO 13485 quality management system.

Implementation Steps

1. Determine PMS activity frequency and depth based on product classification. For Class IIa and above, PMS reports must be updated annually; for Class III and Class IIb active implantable devices, PSURs must be submitted.

2. Utilize feedback handling, complaint management, and vigilance system modules from ISO 13485 and MDR/UKCA QMS, combined with UK-specific MHRA vigilance requirements, to establish data collection processes.

3. Ensure the UK Responsible Person (UKRP) participates in PMS data transmission and reporting obligations.

4. Note the periodic review requirements of notified bodies (e.g., BSI) regarding PMS documentation.

Common Risks

• Failure to update PSURs in a timely manner
• Disconnection between clinical evaluation reports and real-world data
• Not distinguishing between UKCA and CE differences

Preparation Checklist

• Confirm product UKCA classification and minimum PMS documentation frequency
• Appoint a qualified UKRP and sign an agreement covering PMS responsibilities
• Establish or upgrade complaint, feedback, and vigilance processes in the QMS to comply with UK regulations
• Prepare product-specific PMS plan detailing data collection methods, analysis criteria, evaluation intervals, and report templates
• If applicable, initiate PMCF activities, design clinical follow-up plans, and obtain ethics approval
• Allocate resources for periodic PMS reports and PSURs, and submit to MHRA on time
• Establish communication channels with MHRA for serious events, FSCAs, and trend reports
• Maintain a PMS document index in the technical file for notified body review
• Regularly train internal teams and UKRP on UK regulatory changes (e.g., referring to MHRA guidance)

AIMEILI Regulatory Interpretation and Business Impact

Companies often misjudge three points in UK post-market surveillance:

First, assuming UKCA and CE PMS requirements are identical and simply transferring documents. In reality, MHRA has independent requirements on PSUR submission timing, content, and acceptance format, and does not recognize the EU MDR EUDAMED database; submissions must be made manually.

Second, underestimating the substantive capability of the UKRP. Many manufacturers choose low-cost agents lacking regulatory technical background, leading to inaccurate adverse event analysis and report writing, creating data distortion and regulatory risk.

Third, insufficient PMS investment in Class I products. Under UKCA, although Class I non-sterile, non-measuring, non-surgical devices do not require notified body review, MHRA may request PMS data at any time. Failure to demonstrate continuous compliance may result in market removal.

In the early project phase, priority should be given to establishing a basic PMS framework. Even before product launch, plan data collection channels and document templates during registration. Reusable materials include global unified complaint databases, corrective action processes under ISO 13485, and existing CE MDR PMS plans and CER literature searches. However, content that must be localized includes UK market adverse event codes (MHRA internal codes), PSUR cover format, data security clauses in UKRP agreements, and local collaboration paths for clinical follow-up related to NHS products.

For multi-country registration, adopt a 'core PMS plan + country-specific appendices' model. The core plan covers general data collection and analysis methods, while appendices address specific reporting requirements, time windows, and language for each market (UKCA, CE, NMPA, FDA, etc.). This reduces duplicate work and avoids correction risks caused by confusing different jurisdictional requirements. The stability of the UKRP and their responsiveness to regulatory changes are key to long-term registration maintenance; treat them as a strategic partner rather than a cost item.

Frequently Asked Questions

Q: Under UKCA certification, must the PMS report be written by the UKRP?

Regulations require the manufacturer to establish and maintain the PMS system, but specific writing can be done in-house or by a third party. The UKRP's responsibility is to ensure PMS activities comply with UK regulations and to communicate with MHRA on behalf of the manufacturer. In practice, the manufacturer writes a draft report, the UKRP reviews and confirms it before submission, and both parties share responsibility. It is recommended to specify the writing party and review process in the agreement.

Q: If a product has been on the EU market for years, can PMS data be used for the UK?

Yes, but UK market specificity must be assessed. If the clinical use pattern and patient population in the UK are similar to the EU and there are no significant safety signals, EU PMS data can be used as primary evidence. However, UK local adverse event data (from MHRA or the manufacturer's UK complaints) must be supplemented, and data coverage and limitations should be explained in the PMS report. For PMCF, EU clinical follow-up data may be accepted in the UK, but if different healthcare environments are involved, UK centre data may need to be added.

Q: Are Class I self-declared products truly exempt from notified body review of PMS documents?

Yes, Class I self-declared products do not require notified body review, but manufacturers must still maintain complete PMS records. MHRA has the right to request PMS plans, reports, and complaint data during inspections or when product issues arise. Failure to provide them is considered non-compliance and may lead to warnings, fines, or market removal. Therefore, Class I manufacturers are advised to establish a PMS document framework and maintain it regularly.

Note: This FAQ is compiled based on AIMEILI's regulatory practice database, medical device international registration knowledge base, and public regulatory information. Specific projects should refer to the latest requirements of the target country's regulatory authorities and product-specific documentation. Published: 2026-07-26. Updated: 2026-07-26.